Global Blood Therapeutics, Inc. (NASDAQ:GBT) is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, GBT is expected to report 3Q20 loss of $ 0.73 per share from revenue of $ 43.98 million.
For the full year, analysts anticipate top line of $ 144.68 million, while looking forward to loss of $ 3.41 per share bottom line.
Previous Quarter Performance
Global Blood Therapeutics, Inc. unveiled loss for the second quarter of $ 0.86 per share, from the revenue of $ 31.50 million. The consensus estimates are loss of $ 1.15 per share from $ 18.81 million in revenue. The bottom line results beat street analysts by $ 0.29 or 25.22 percent, at the same time, top line results outshined analysts by $ 12.69 million or 67.46 percent.
Stock Performance
Shares of Global Blood Therapeutics, Inc. traded up $ 7.89 or 14.61 percent on Wednesday, reaching $ 61.88 with volume of 1.84 million shares. Global Blood Therapeutics, Inc. has traded high as $ 63.03 and has cracked $ 54.51 on the downward trend
The closing price of $ 61.88, representing a 35.14 % increase from the 52 week low of $ 39.95 and a 38.33 % decrease over the 52 week high of $ 87.54.
The company has a market capital of $ 3.80 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 13th October 2020, maintained by Morgan Stanley at Equal-Weight rating, with $ 68.00 target price.
- On 6th October 2020, initiated by Evercore ISI at Outperform rating, with $ 102.00 target price.
Conference Call
Global Blood Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.gbt.com
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
